TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00566332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
Study: NCT04780191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoRegulator®
Description: Trans-spinal DC stimulation paired with peripheral DC stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoRegulator®
Description: Trans-spinal DC stimulation paired with peripheral DC stimulation
Study: NCT01884155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood therapy
Study: NCT02331706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
Study: NCT03630185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-manufactured compression hosiery (Isobar)
Description: The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off-the-rack stockings (Sigvaris)
Description: Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
Study: NCT01688427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard IPV Assessment
Description: Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard IPV Assessment
Description: Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard DOVE Intervention
Description: Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
Study: NCT00032110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT01414855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
Study: NCT00032110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00901394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B12-Folic Acid, nitrous oxide
Description: IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (NO) and placebo
Description: 60% nitrous oxide anesthesia plus saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide (NO) and placebo
Description: 60% nitrous oxide anesthesia plus saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen nitrogen
Description: 60% air and oxygen mix.
Study: NCT02463331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate
Description: One pill of chloroquine diphosphate per day until the end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone 5-15 mg/day until the end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone 5-15 mg/day until the end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine 1-2mg/Kg/day until the end of the study
Study: NCT00561301

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GemDOx
Description: gemcitabine oxliplatin
Study: NCT01620658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.5mm XPF cap
Description: Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material.
Study: NCT03559413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Individual peptide vaccination with adjuvant GM-CSF and Imiquimod
Description: Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
Study: NCT06683157

Intervention type: DIAGNOSTIC_TEST
Intervention: not drug
Description: Patients presenting with symptomatic ICVT will be examined by CCUS for both legs. Inclusion/exclusion criteria will be checked. No anticoagulation therapy is given. Compression stockings at the calf length will be prescribed for 30 days.~CCUS will be repeated on day 5±2, day 10±2, and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on.
Study: NCT03546920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIGN Intervention Phase
Description: Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives.
Study: NCT03624686

Intervention type: OTHER
Intervention: peripheral blood
Description: draw peripheral blood
Study: NCT01620658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.3mm XPF cap
Description: Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cap
Description: Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
Study: NCT02310724

Intervention type: OTHER
Intervention: TODAY cohort
Description: This protocol is observation only and involves no intervention, care, treatment, or management.
Study: NCT05999058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation
Description: The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
Study: NCT01524224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously
Study: NCT03220932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery combined with HIPEC
Description: Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy and bevacizumab (CT-BEV)
Description: Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
Study: NCT04528017

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study: NCT02930382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baroreflex assessment
Study: NCT01175265

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: respiratory biofeedback
Description: In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
Study: NCT01794312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4020

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT03293849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
Study: NCT01736072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopic Surgery
Description: The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
Study: NCT03923829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: systemic administration of Zinc sulfate with scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: scaling and root planing
Study: NCT02960308

Intervention type: RADIATION
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo WNCTP scan
Study: NCT02765854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT06132529

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Magnetic Resonance Imaging (MRI) Scan
Description: Imaging of the brain

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Magnetic Resonance Imaging (MRI) Scan
Description: Imaging of the brain

Intervention type: OTHER
Intervention: Speech Sample
Description: Recorded reading aloud of pre-written words and sentences

Intervention type: OTHER
Intervention: Speech Sample
Description: Recorded reading aloud of pre-written words and sentences

Intervention type: OTHER
Intervention: Electronic Daily Headache Diary
Description: Headache diary to provide information about headaches experience that day.
Study: NCT01736072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Assisted Laparoscopic Surgery
Description: The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
Study: NCT04851314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICU certified ventilator
Description: Examine anesthetic consumption rates
Study: NCT03694691

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
Study: NCT00670046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: given orally

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care follow-up
Description: participant follow the standard of care for patient with metastatic prostate cancer
Study: NCT03807908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tape
Description: The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Tape
Description: One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index).
Study: NCT01771484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External automated abdominal binder
Description: Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External automated abdominal binder
Description: Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
Study: NCT01988935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
Study: NCT00325949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release hydrocodone and acetaminophen (Vicodin CR)
Description: 2 tablets BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/acetaminophen extended release (Vicodin CR)
Description: 1 tablet BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets BID
Study: NCT02274766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Description: Oral capsules to be administered once nightly at bedtime, for 13 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules to be administered once nightly at bedtime, for 13 weeks.
Study: NCT04562038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)
Description: The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
Study: NCT02390362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: Subjects randomized to MMF, will continue MMF as scheduled by the investigator
Study: NCT02367859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT00413777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
Study: NCT00444951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03990441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS Placebo
Description: Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
Study: NCT02465762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrashape Fat reduction
Description: Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
Study: NCT01875068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultations between NPs and PAs and their supervising physicians
Description: Required discussion with physician prior to referral by a nurse practitioner or physician assistant

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: versus NPs and PAs who are not required to discuss patient referrals (control group).